Latest Capital Raising News

Western Yilgarn has revealed high-grade, shallow gallium mineralisation from re-assayed drill pulps at its Cardea 1 Project, highlighting potential for a large-scale critical minerals resource in Western Australia’s Darling Range.

Augustus Minerals has launched a follow-up drilling campaign at its Clifton East prospect within the Music Well Gold Project, aiming to refine the strike and dip of promising gold mineralisation discovered earlier this year.

Corella Resources has completed due diligence on the Chobe Project tenements, advancing its plan to acquire a 75% stake from Caprice Resources. The project, rich in carbonatite potential, awaits final capital raising and regulatory approvals.

Lachlan Star’s maiden diamond drilling at New Waverley confirms shallow, high-grade gold mineralisation within a continuous shear corridor, setting the stage for an extensive follow-up drilling campaign.

Tasman Resources appoints experienced director Adam Turnbull as it raises $4.05 million to fund expanded drilling at Parkinson Dam and Lake Torrens projects, positioning for a potentially transformative 2026 exploration year.

Evion Group confirms high-grade fluorspar assays up to 88.15% CaF2 at its Carp Project in Nevada, validating a large, near-surface mineralised system. The company plans an extensive exploration program to capitalise on the US critical minerals demand.

Desert Metals has expanded its Tiogo gold anomaly at Tengrela South, Côte d'Ivoire, by over 3km northwards, unveiling a new high-priority target ready for drilling.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

TruScreen Group has secured NZ$1.82 million through an oversubscribed placement, underscoring investor confidence amid its global cervical screening expansion. The company also announced a renounceable rights issue and attaching options, both subject to shareholder approval.

Alternative Investment Trust (AIQ) has issued 7.39 million units at A$1.38 each, raising A$10.2 million from wholesale investors without a product disclosure statement. The capital raise aligns with AIQ’s adjusted net tangible asset value and complies with Corporations Act requirements.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

1414 Degrees Limited has responded to an ASX price query after its shares jumped from $0.056 to $0.097 in days, confirming no undisclosed information but highlighting progress in aerospace and energy projects.